PCM
CBAY

Prelude Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Prelude Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,973
Closed -$95.7K – 1474
2023
Q1 		$95.7K Buy
+10,973
New +$87.8K 0.01% 955
2020
Q3 		– Hold
0
– – – 2731
2020
Q2 		– Hold
0
– – – 2556
2019
Q3 		– Sell
-767
Closed -$5K – 2335
2019
Q2 		$5K Buy
+767
New +$8.69K ﹤0.01% 1526
2019
Q1 		– Sell
-905
Closed -$7K – 2408
2018
Q4 		$7K Buy
905
+95
+12% +$904 ﹤0.01% 1489
2018
Q3 		$9K Buy
+810
New +$10.1K ﹤0.01% 1492
2018
Q2 		– Sell
-906
Closed -$12K – 2090
2018
Q1 		$12K Buy
906
+416
+85% +$5.17K ﹤0.01% 1345
2017
Q4 		$5K Sell
490
-6,610
-93% -$56.5K ﹤0.01% 1269
2017
Q3 		$57K Buy
+7,100
New +$48K 0.01% 1065

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.98B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return